Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease
Overview
Clinicians know little about Creutzfeldt Jakob disease, and they are not proficient in the diagnostic criteria of Creutzfeldt Jakob disease, so it is easy to misdiagnose or delay the diagnosis. As a rare central nervous system disease, it is necessary, feasible and practical to evaluate the diagnostic criteria of Creutzfeldt Jakob disease.
Full Title of Study: “Follow up Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease (WS / T 562-2017)”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: January 1, 2020
Detailed Description
To master the clinical application of the diagnosis of Creutzfeldt Jakob disease (WS / T 562-2017) and the problems in the implementation process; The rationality, practicability and operability of the diagnostic criteria were evaluated scientifically; Reduce the misdiagnosis rate; To provide clinical basis and suggestions for further improving the diagnostic criteria. Through consulting the literature of Creutzfeldt Jakob disease, the clinical manifestations, laboratory examination, auxiliary examination and pathological results of Creutzfeldt Jakob disease were analyzed and compared with the current diagnostic criteria; The clinical diagnosis and misdiagnosis of Creutzfeldt Jakob disease were analyzed; To train medical staff at all levels to apply the diagnostic criteria of Creutzfeldt Jakob disease, and to discuss the clinical cases of Creutzfeldt Jakob disease in many hospitals.
Interventions
- Diagnostic Test: laboratory examination, auxiliary examination, pathological results
- Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
Arms, Groups and Cohorts
- Patients with Creutzfeldt Jakob disease
- Patients with Creutzfeldt Jakob disease
Clinical Trial Outcome Measures
Primary Measures
- Clinical manifestations
- Time Frame: 1 year
- Clinical manifestations of patients
Participating in This Clinical Trial
Inclusion Criteria
- Patients with Creutzfeldt Jakob disease Exclusion Criteria:
- none
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Peking University Third Hospital
- Collaborator
- Centers for Disease Control and Prevention, China
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Li Xiaogang, Principal Investigator, Peking University Third Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.